170 related articles for article (PubMed ID: 9218193)
21. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
Gosse P
Expert Rev Cardiovasc Ther; 2006 May; 4(3):319-33. PubMed ID: 16716093
[TBL] [Abstract][Full Text] [Related]
22. The clinical relevance of pharmacological blood pressure lowering mechanisms.
Lonn E
Can J Cardiol; 2004 Aug; 20 Suppl B():83B-88B. PubMed ID: 15309210
[TBL] [Abstract][Full Text] [Related]
23. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
White WB
Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
[TBL] [Abstract][Full Text] [Related]
24. [The rationale for drug combinations in the therapy of arterial hypertension].
Salvetti A; Virdis A; Di Venanzio L
Ann Ital Med Int; 1993 Oct; 8 Suppl():107S-110S. PubMed ID: 8117517
[TBL] [Abstract][Full Text] [Related]
25. Now or never: optimal antihypertensive therapy in the elderly.
Prisant LM
Prev Cardiol; 2008; 11(4):201-9. PubMed ID: 19476572
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacology of antihypertensive therapy.
Taylor AA; Pool JL
Semin Nephrol; 2005 Jul; 25(4):215-26. PubMed ID: 16202694
[TBL] [Abstract][Full Text] [Related]
27. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
28. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
29. [Goal blood pressure values from the nephrologic viewpoint].
Hörl WH
Wien Med Wochenschr; 1999; 149(23-24):629-32. PubMed ID: 10721158
[TBL] [Abstract][Full Text] [Related]
30. Fixed low-dose combination therapy for hypertension.
Waeber B
Curr Hypertens Rep; 2002 Aug; 4(4):298-306. PubMed ID: 12117457
[TBL] [Abstract][Full Text] [Related]
31. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
32. [Combination therapy in primary hypertension].
Halawa B
Pol Merkur Lekarski; 1998 Jan; 4(19):35-8. PubMed ID: 9553408
[TBL] [Abstract][Full Text] [Related]
33. [Refractory hypertension--principles of combination therapy].
Hitzenberger G
Acta Med Austriaca; 1995; 22(3):43-5. PubMed ID: 8571749
[TBL] [Abstract][Full Text] [Related]
34. The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril.
Chatzikyrkou C; Haller H; Menne J
Expert Opin Pharmacother; 2009 Aug; 10(11):1833-40. PubMed ID: 19527194
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
Roca-Cusachs A; Schmieder RE; Triposkiadis F; Wenzel RR; Laurent S; Kohlmann O; Fogari R;
J Hypertens; 2008 Apr; 26(4):813-8. PubMed ID: 18327093
[TBL] [Abstract][Full Text] [Related]
36. [Fixed-combination of losartan/hydrochlorothiazide 100 mg/25 mg. Tolerability and efficacy on blood pressure measured in the practice and for 24 hours].
Förster A; Smolka W; Jung C; Bestehorn K
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():111-8. PubMed ID: 17955788
[TBL] [Abstract][Full Text] [Related]
37. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
Roberts ME; Epstein BJ
J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
[TBL] [Abstract][Full Text] [Related]
38. Hypertension: which aspects of hypertension should we impact on and how?
Zanchetti A; Waeber B
J Hypertens Suppl; 2006 Aug; 24(5):S2-5. PubMed ID: 16936532
[TBL] [Abstract][Full Text] [Related]
39. [Fixed antihypertensive drug combinations].
Waeber B
Ther Umsch; 1999 Jan; 56(1):33-6. PubMed ID: 10067132
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy.
Reid JL
J Hum Hypertens; 1995 Aug; 9 Suppl 4():S19-23. PubMed ID: 7674268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
